Time plays a major role in seizure evaluation and treatment. Acute repetitive seizures and status epilepticus are medical emergencies that require immediate assessment and treatment for optimal therapeutic response. Benzodiazepines are considered the first-line agent for rapid seizure control. Thus, various routes of administration of benzodiazepines have been studied to facilitate a quick, effective, and easy therapy administration. Choosing the right agent may vary based on the drug and route properties, patient’s environment, caregiver’s skills, and drug accessibility. The pharmacokinetic and pharmacodynamic aspects of benzodiazepines are essential in the decision-making process. Ultimately, agents and routes that give the highest bioavailability, fastest absorption, and a modest duration are preferred. In the outpatient setting, intranasal and buccal routes appear to be equally effective and more rapidly administered than rectal diazepam. On the other hand, in the inpatient setting, if available, the IV route is ideal for benzodiazepine administration to avoid any potential absorption delay. In this article, we will provide an overview and comparison of the various routes of benzodiazepine administration for acute control of repetitive seizures and status epilepticus.
Purpose A study was conducted to evaluate the accuracy of Google Translate (Google LLC, Mountain View, CA) when used to translate directions for use and counseling points for the top 100 drugs used in the United States into Arabic, Chinese (simplified), and Spanish. Methods Directions for use and common counseling points for the top 100 drugs were identified by 2 clinicians. This information was translated from English to Arabic, Chinese (simplified), and Spanish using Google Translate. Two nonclinician, bilingual native speakers of each language back-translated the Google Translate translation into English and determined if the sentence made sense in their native language. Two clinicians reviewed the back-translations to determine the clinical significance of each inaccurate translation. Results For the top 100 drugs, 38 unique directions for use and 170 unique counseling points were identified for translation. For the 38 directions for use, 29 (76.3%) of the Arabic translations were accurate, 34 (89.5%) of the Chinese (simplified) translations were accurate, and 27 (71%) of the Spanish translations were accurate. For the 170 counseling points, 92 (54.1%) of the Arabic translations were accurate, 130 (76.5%) of the Chinese (simplified) translations were accurate, and 65 (38.2%) of the Spanish translations were accurate. Of the 247 inaccurate translations, 72 (29.1%) were classified as highly clinically significant or potentially life-threatening. Conclusion Certified translators should be used to translate directions for use and common counseling points for prescription medications into Arabic, Chinese (simplified), and Spanish. Clinicians should be aware of the risk of inaccurate translation when Google Translate is used.
Levetiracetam is an antiseizure drug commonly utilized in the neurocritical care (NCC) environment for the treatment of seizures, status epilepticus, and as a prophylactic therapy in certain situations.Levetiracetam's exact mechanism of action is unknown; however, its main antiseizure effect is proposed to be neurotransmitter modulation through binding to synaptic vesicle glycoprotein 2A. 1,2 Levetiracetam has also been shown to have modulating effects at the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor. 3 While efficacious, levetiracetam treatment has also been associated with the risk of developing behavioral adverse events
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.